The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•7 May 2026•

1 min read

Novartis Breaks Ground on New Texas RLT Facility Amid $23B US Investment

Key Facts

1Novartis broke ground on a new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas.

2The facility is part of a broader $23 billion investment in US manufacturing and research by the company.

3The site, which is the company's fifth RLT facility in the US, is expected to become operational in 2028.

Novartis has officially broken ground on a new 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas. This project is a key component of the company's broader $23 billion investment strategy focused on expanding its manufacturing and research footprint across the United States. The site is slated to become operational by 2028, marking the company's fifth specialized RLT facility in the country. By establishing this plant, Novartis aims to strengthen the domestic supply chain for advanced oncology treatments and scale the delivery of personalized therapies. This expansion aligns with the company's goal of integrating radioligand therapies into earlier stages of cancer treatment. The investment underscores a bullish long-term outlook for the company's high-growth oncology segment.